Company press releases
Tid | Selskap | Tittel | Sektor | Kategori |
---|---|---|---|---|
12 Nov 2021 08:00 CET |
LYTIX BIOPHARMA AS | Lytix presents encouraging preclinical data in triple negative breast cancer in collaboration with Weill Cornell Medicine | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
22 Oct 2021 09:45 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma granted European Patent for LTX-315 in combination with chemotherapeutic agent | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
20 Oct 2021 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS to Present at Investordagene 2021 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
22 Sep 2021 18:20 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
27 Aug 2021 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
20 Aug 2021 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of first half and second quarter 2021 results, Friday 27 August | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
15 Jul 2021 11:50 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma initiates the Phase II combination study in the US with LTX-315 and Pembrolizumab in patients with solid tumors | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
14 Jun 2021 08:39 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Company presentation in connection with first day of trading on Euronext Growth Oslo | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
14 Jun 2021 00:05 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Publication of Information Document | 20103010 Biotechnology | Prospekt / opptaksdokument |